Diamyd Medical Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Diamyd Medical (STO:DMYD B) Full Year 2024 Results

Key Financial Results

• Net loss: kr151.9m (loss widened by 31% from FY 2023).
• kr1.52 loss per share (further deteriorated from kr1.48 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Diamyd Medical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 45%. Earnings per share (EPS) missed analyst estimates by 20%.

Looking ahead, revenue is expected to decline by 20% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 17%.

Performance of the Swedish Biotechs industry.

The company's shares are down 7.2% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Diamyd Medical has 6 warning signs (and 4 which shouldn't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.